Uwe Platzbecker

Trials

Studies that name Uwe Platzbecker as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:58 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT06243458 · RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

  GCP-Service International West GmbH · active not recruiting · Low Risk Myelodysplastic Syndromes · principal investigator
• Ph2
  NCT05829434 · Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS

  Uwe Platzbecker · withdrawn · Acute Myeloid Leukemia, Myelodysplastic Neoplasm · principal investigator
• Ph2
  NCT05583552 · Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy

  GCP-Service International West GmbH · completed · Myelodysplastic Syndromes, Acute Myeloid Leukemia · principal investigator
• Ph2
  NCT05178342 · Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948

  University of Leipzig · terminated · Myelodysplastic Syndromes, Anemia · principal investigator
• N/A
  NCT04889729 · GENOMED4ALL: Improving MDS Classification and Prognosis by AI

  Istituto Clinico Humanitas · unknown · Myelodysplastic Syndromes · principal investigator
• Ph2
  NCT04712942 · Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat

  University of Leipzig · completed · Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Minimal Residual Disease · principal investigator
• Ph2
  NCT04061239 · Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML

  GWT-TUD GmbH · completed · MDS, AML · study chair
• Ph2
  NCT03824080 · Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes

  GWT-TUD GmbH · completed · Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome, Low-risk Myelodysplastic Syndrome · principal investigator
• Ph2
  NCT02992860 · Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY

  GWT-TUD GmbH · terminated · Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) · principal investigator
• N/A
  NCT02867085 · Study Investigating the Interactions of Bone and Hematopoiesis in the Elderly

  Technische Universität Dresden · completed · Myelodysplastic Syndromes · principal investigator
• Ph3
  NCT02688140 · Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia

  Technische Universität Dresden · completed · Acute Promyelocytic Leukemia · principal investigator
• Ph2
  NCT02446145 · A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients

  Technische Universität Dresden · terminated · Acute Myeloid Leukemia · principal investigator
• Ph2
  NCT02335268 · Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia

  Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH · completed · Myelodysplastic Syndromes · study director
• Ph2
  NCT01462578 · Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)

  Technische Universität Dresden · completed · Acute Myelocytic Leukemia, Myelodysplastic Syndrome · principal investigator
• Ph2
  NCT01111448 · Temsirolimus in Myelodysplastic Syndrome (MDS)

  Technische Universität Dresden · terminated · Myelodysplastic Syndrome · principal investigator
• Ph1
  NCT00923234 · Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes

  Technische Universität Dresden · terminated · Myelodysplastic Syndromes, Acute Myelogenous Leukemia · principal investigator
• Ph2
  NCT00720850 · Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

  Technische Universität Dresden · terminated · Myelodysplastic Syndromes, Acute Myelogenous Leukemia · study chair
• Ph3
  NCT00422890 · Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)

  Technische Universität Dresden · completed · Myeloid Leukemia, Myelodysplastic Syndrome · principal investigator
• Ph2/Ph3
  NCT00117702 · Prevention of the Graft-Versus-Host-Disease in Patients After Stem Cell Transplantation With Tacrolimus and Everolimus

  Technische Universität Dresden · terminated · Graft vs Host Disease · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 22:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.